Use of inhibitors of the renin-angiotensin system

Details Use of inhibitors of the renin-angiotensin system Use of inhibitors of the renin-angiotensin system

2011-08-16

2011-08-16

Hui, San-Ming (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S221000

Reexamination Certificate

active

07998953

ABSTRACT:
It has been found that inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and are thus useful in treatment of the symptoms and signs of aging. These inhibitors may also be used to enhance function in healthy subjects.

REFERENCES:
patent: 5049553 (1991-09-01), Sudilovsky
patent: 5151432 (1992-09-01), Vincent et al.
patent: 5246957 (1993-09-01), Cozzi et al.
patent: 5374643 (1994-12-01), Atwal et al.
patent: 5464854 (1995-11-01), dePadova
patent: 5468757 (1995-11-01), Jakubowski et al.
patent: 5538991 (1996-07-01), Ashton et al.
patent: 5550118 (1996-08-01), Jakubowski et al.
patent: 5559135 (1996-09-01), Ashton et al.
patent: 5591762 (1997-01-01), Hauel et al.
patent: 5591767 (1997-01-01), Mohr et al.
patent: 5604236 (1997-02-01), Jakubowski et al.
patent: 5846989 (1998-12-01), Bonnert et al.
patent: 5846990 (1998-12-01), Murugesan et al.
patent: 5952305 (1999-09-01), Pfeffer et al.
patent: 6103732 (2000-08-01), Amberg et al.
patent: 6139847 (2000-10-01), Chobanian et al.
patent: 6197505 (2001-03-01), Norberg et al.
patent: 6258032 (2001-07-01), Hammesfahr
patent: 6335451 (2002-01-01), Kleemann et al.
patent: 6420412 (2002-07-01), Palepu et al.
patent: 6448248 (2002-09-01), Amberg et al.
patent: 6670367 (2003-12-01), Amberg et al.
patent: 2004/0122096 (2004-06-01), Lang et al.
patent: 44 20 102 (1994-06-01), None
patent: 0 482 498 (1991-10-01), None
patent: 0459136 (1991-12-01), None
patent: 0 474 438 (1992-03-01), None
patent: 0 488 059 (1992-06-01), None
patent: 0 702 012 (1996-03-01), None
patent: 2 241 890 (1991-09-01), None
patent: WO 92/10188 (1992-06-01), None
patent: WO 93/18794 (1993-09-01), None
patent: WO 97/13513 (1997-04-01), None
patent: WO 97/13513 (1997-04-01), None
patent: WO 97/21436 (1997-06-01), None
patent: WO 97/21436 (1997-06-01), None
patent: WO 97/38981 (1997-10-01), None
patent: WO 98/11066 (1998-03-01), None
patent: WO 98/19690 (1998-05-01), None
patent: WO 98/33780 (1998-08-01), None
patent: WO 98/55453 (1998-12-01), None
Strohmenger et al., Resucitation, 1997;35:61-68.
Milavetz et al., J Am Coll Cardiol., 1996;27-714-719.
Wienen et al., British Journal of Pharmacology, 1993;110:245-252.
Milavetz et al., J. Am . Coll. Cardiol., 1996;27:714-719.
Brix et al. (Sep. 16, 1996) “Bartter's syndrome. A condition with chronic hypokalemia,”Ugeskr Laeger158(38):5277-5280, (abstract only).
Bussmann et al. (1988) “Angiotensin-Converting-Enzym-Hemmer bei Angina pectoris,”Dtsch. med. Wschr.133:548-550.
Cameron et al. (1993) “Potential Therapeutic Approaches to the Treatment or Prevention of Diabetic Neuropathy: Evidence from Experimental Studies”Diabetic Medicine10(7):593-605.
Costelli et al. (1993) “Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model,”J. Clin. Invest.92(6):2783-2789.
Donatelli et al. (1991) “Comparison of the Renal Effects of Enalapril and Nifedipine in Obese Patients with Hypertension and Non-Insulin-Dependent Diabetes Mellitus”Current Therapeutic Research50(2):312-316.
Fukuzawa et al. [1997]Immunopharmacology36:49-55.
Goldberg et al. (1995) “Pentoxifylline for Treatment of Cancer Anorexia and Cachexia? A Randomized, Double-Blind, Placebo-Controlled Trial,”Journal of Clinical Oncology13(11):2856-2859.
Hall [1986] “Regulation of glomerular filtration rate and sodium excretion by angiotensin II,”Federation Proceedings45(5):1431-1437.
Hayashi et al. [1989]J. Med. Chem.32:289-297.
Kim et al. [1995] “Trophic effects of angiotensin II on neonatal rat cardiac myocytes are mediated by cardiac fibroblasts,”American Journal of Physiology Endocrinology and Metabolism269(2):E426-E437.
Levine et al. [1990] “Elevated Circulating Levels of Tumor Necrosis Factor in Severe Chronic Heart Failure,”The New England Journal of Medicine323(4):236-41.
Maltoni et al., (Mar. 1997) “Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients,”Support Care Cancer5(2):130-135.
Mazzocchi et al. [1985] “Trophic effects of potassium loading on the rat zona glomerulosa: permissive role of ACTH and angiotension II”Acta Endocrinologica108(1):98-103.
Mimran et al. [1984] “Renal Adaptation to Sodium Deprivation”The American Journal of Medicine76(5B):14-21.
Munzenmaier et al. [1995] “Angiotensin II mediates a sustained rise in nuclear and cytoplasmic calcium via multiple receptor subtypes”American Journal of Physiology—Heart and Circulatory Physiology269(2):H565-H570.
Oliff, (Jul. 15, 1988), Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania, “The Role of Tumor Necrosis Factor (Cachectin) in Cachexia”Cell54:141-142.
Texter et al. [1993] “The QUinapril Ischemic Event Trial (QUIET) Design and Methods: Evaluation of Chronic ACE Inhibitor Therapy After Coronary Artery Intervention,” pp. 273-282.
Tracey et al., (1988) “Cachectin: A Hormone that Triggers Acute Shock and Chronic Cachexia,”The Journal of Infectious Diseases157(3):413-420.
Tracey et al. (Mar. 1988) “Cachectin/Tumor Necrosis Factor Induces Cachexia, Anemia, and Inflammation,”J. Exp. Med.167:1211-1227.
Winkelmann et al.European Heart Journal, XX, The European Society of Cardiology12:355 (abstract).
Ahmed, S. “Angiotensin receptor antagonists delay nitric oxide-deficient stroke in stroke-prone rats”European Journal of Pharmacology, Aug. 20, 1997, pp. 39-45, vol. 333, No. 1.
Bulpitt, C.J. et al. “The hypertension in the very elderly trial (HYVET)”Journal of Human Hypertension, Aug. 1994, pp. 631-632, vol. 8, No. 8.
Bursztyn, M. et al. “Hypertension in the aging patient. Implications for the selection of drug therapy”Journal of the American Geriatrics Society, 1989, pp. 814-818, vol. 37, No. 8.
Bussmann, W.D. et al. “Angiotensin-converting-enzym-hemmer bei angina pectoris”Deutsche Medizinische Wochenschrift, De, Stuttgart, 1988, pp. 548, 550, vol. 113, No. 14.
Cameron, N.E. et al. “Potential therapeutic approaches to the treatment or prevention of diabetic neuropathy: Evidence from experimental studies”Diabetic Medicine, 1993, pp. 593-605, vol. 10, No. 7.
Donatelli, M. et al. “Comparison of the renal effects of enalapril and nifedipine in obese patients with hypertension and non-insulin-dependent diabetes mellitus”Curr. Ther. Res., 1991, pp. 312-316, vol. 50, No. 2.
Gohlke, P. et al. “Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke prone spontaneously hypertensive rats” Hypertension, 1997, pp. 478-482, (Abstract).
Hall, J.E. “Regulation of glomerular filtration rate and sodium excretion by angiotensin II”Federation Proceedings, Apr. 1986, pp. 1431-1437, vol. 45, No. 5.
Kim, N.N. et al. “Trophic effects of angiotensin II on neonatal rat cardiac myocytes are mediated by cardiac fibroblasts”American Journal of Physiology, Endocrinology and Metabolism, 1995, pp. E426-E437, vol. 296/3, No. 32-33. (Abstract).
Langstein, H.N. et al. “Mechanisms of cancer cachexia”Hematol. Oncol. Clin. North. Am., Feb. 1991, pp. 103-123, vol. 5, No. 1. (Abstract).
Lutterotti Von N. et al. “Angiotensin II receptor antagonist delays renal damage and stroke in salt-loaded dahl salt-sensitive rats”Journal of Hypertension, Current Science, 1992, pp. 949-957, vol. 10, No. 9.
MacLeod, A. B. et al. “The role of blood pressure and aldosterone in the production of hemorrhagic stroke in captopril-treated hypertens

Affiliated with

Also associated with

Rating

Use of inhibitors of the renin-angiotensin system does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of inhibitors of the renin-angiotensin system, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of inhibitors of the renin-angiotensin system will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2695613